Serum tissue inhibitor of metalloproteinase 1 (TIMP-1) and vascular endothelial growth factor A (VEGF-A) are associated with prognosis in esophageal cancer patients

Kozłowski, Mirosław; Laudański, Wojciech; Mroczko, Barbara; Szmitkowski, Maciej; Milewski, Robert; Łapuć, Grzegorz

doi:10.2478/ams-2013-0017

Cited by 21 publications

(17 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…28 In a more recent study, a comparison of serum levels between 89 patients with esophageal cancer (63 ESCC and 26 EAC) with a control group showed that high serum VEGF-A is associated with tumor progression and unfavorable prognosis in patients. 64 This study showed that VEGF is not only an intratumoral biomarker, but also a circulating marker for esophageal cancer, which is in concordance with other cancer types. [65][66][67] Besides VEGF, other angiogenic-related factors have been reported to have clinical relevance.…”

supporting

confidence: 76%

The potential of targeted antiangiogenesis therapies in the treatment of esophageal cancer

Xu¹,

Li²,

Cheung

2015

GICTT

View full text Add to dashboard Cite

Esophageal cancer is one of the most lethal cancers worldwide and its incidence is increasing at an alarming rate. Despite advances in surgical techniques and combined multimodality therapy, the survival rate of esophageal cancer remains poor. Clearly, the time is ripe for introducing novel strategies such as targeted therapies to improve treatment outcome. The significance of angiogenesis and angiogenic factors in the progression and aggressiveness of esophageal cancer is well documented. However, although increasing numbers of antiangiogenic agents designed to inhibit angiogenesis through multiple mechanisms have been developed in the past few decades, and some of them have shown promising results in preclinical and clinical studies, there is as yet no antiangiogenic agent approved for esophageal cancer. This review provides a summary of angiogenesis and vasculogenesis, the molecular mechanisms that regulate these processes, and the strategies for targeting angiogenesis in tumors. We will also present the rationale and challenges of antiangiogenic therapy, and the antiangiogenic agents that have been tested in preclinical studies or clinical trials for esophageal cancer. With further research bringing a deeper understanding of the molecular mechanisms involved in angiogenesis, and as new angiogenesis-targeting agents continue to evolve, there are reasons to be optimistic that targeting angiogenesis may bring new opportunities to cure this highly lethal disease.

show abstract

supporting

confidence: 76%

The potential of targeted antiangiogenesis therapies in the treatment of esophageal cancer

Xu¹,

Li²,

Cheung

2015

GICTT

View full text Add to dashboard Cite

show abstract

“…The catalytic activity of MMPs can be inhibited by tissue inhibitors of metalloproteinases. A high expression of TIMPs (especially TIMP-1) has been found in esophageal, 41 pancreatic, 42 and gastric 43 cancers.…”

Section: Discussionmentioning

confidence: 99%

Plasma levels and diagnostic utility of VEGF, MMP-9, and TIMP-1 in the diagnosis of patients with breast cancer

Ławicki

Głażewska

Będkowska

et al. 2016

OTT

View full text Add to dashboard Cite

Vascular endothelial growth factor (VEGF), matrix metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 may play a role in the pathogenesis of cancer disease. We investigated their levels and utility in comparison to cancer antigen (CA) 15-3 in patients with breast cancer (BC) and in relation to the control groups. The study included 100 women with BC, 50 patients with benign breast tumor, and 50 healthy women. The plasma levels of the tested parameters were determined using enzyme-linked immunosorbent assay, while CA 15-3 with chemiluminescent microparticle immunoassay. The results demonstrated significant differences in the concentration of the tested parameters and CA 15-3 between groups of patients with BC and healthy patients or patients with benign breast tumor. The plasma levels of VEGF and tissue inhibitor of metalloproteinase-1 were significantly higher in advanced tumor stages. The tested parameters were comparable to CA 15-3 values of the diagnostic sensitivity, specificity, the predictive values of positive and negative test results, and the area under the receiver-operating characteristic curve. The combined use of the tested parameters with CA 15-3 resulted in the increase in sensitivity, negative predictive value, and area under the receiver-operating characteristic curve, especially in the combination of VEGF with tumor marker (84%, 73%, 0.888, respectively). These findings suggest the usefulness of the tested parameters in the diagnosis of BC. VEGF, especially in combination with CA 15-3, showed the highest usefulness in the diagnosis of early BC.

show abstract

“…VEGF is expressed in various cells including myofibroblasts, fibroblasts and endothelial cells in normal tissues, and plays a role in the physiological angiogenesis such as that required for tissue injury healing [1,9,10]. VEGF is also highly expressed by most human cancers (e.g., breast, ovarian, colon, pancreatic and esophageal cancer) and its expression often correlates with tumor progression and poor prognosis [11][12][13][14][15][16][17]. Several studies have demonstrated the critical requirement of VEGF for tumor angiogenesis and growth [18][19][20].…”

Section: Introductionmentioning

confidence: 99%

Aberrant, ectopic expression of VEGF and VEGF receptors 1 and 2 in malignant colonic epithelial cells. Implications for these cells growth via an autocrine mechanism

Ahluwalia

Jones

Szabó

et al. 2013

Biochemical and Biophysical Research Communications

View full text Add to dashboard Cite

show abstract

Serum tissue inhibitor of metalloproteinase 1 (TIMP-1) and vascular endothelial growth factor A (VEGF-A) are associated with prognosis in esophageal cancer patients

Cited by 21 publications

References 33 publications

The potential of targeted antiangiogenesis therapies in the treatment of esophageal cancer

The potential of targeted antiangiogenesis therapies in the treatment of esophageal cancer

Plasma levels and diagnostic utility of VEGF, MMP-9, and TIMP-1 in the diagnosis of patients with breast cancer

Aberrant, ectopic expression of VEGF and VEGF receptors 1 and 2 in malignant colonic epithelial cells. Implications for these cells growth via an autocrine mechanism

Contact Info

Product

Resources

About